ホルモン補充療法の世界市場：洞察、競合情勢、市場予測：2030年

世界のホルモン補充療法の市場規模は、2024年から2030年までの予測期間中に6.48％のCAGRで拡大すると予測されています。ホルモン補充療法市場は、特に更年期障害や骨粗鬆症などのホルモン性疾患や標的疾患の負担増により、大幅な市場成長が見込まれています。さらに、低ホルモン関連疾患に罹患しやすい高齢者人口の増加、女性の更年期障害管理に対する意識の高まり、抗老化療法や生殖周期促進療法などの再生医療に対する需要の増加は、ホルモン補充療法の需要急増の一助となるとみられています。さらに、ホルモン補充療法に関する研究開発活動の増加、例えば、有効性を向上させるための経皮パッチの研究などが、市場におけるホルモン補充療法の需要を増加させると予測されています。その他の活動として、薬剤の承認や上市の急増、市場における主要プレイヤーの存在などが、ホルモン補充療法の必要性を市場にもたらすと期待されています。

ホルモン補充療法市場を牽引する主な要因の1つは、更年期障害の管理に対する女性の意識が世界中で高まっていることです。

女性の閉経の世界平均年齢は約50歳です。女性のエストロゲンとプロゲステロンの産生レベルは、50歳を過ぎると著しく低下します。下垂体は、卵胞刺激ホルモン（FSH）の産生を増加させることによって、エストロゲンとプロゲステロンの産生量の減少を補います。これは、女性の場合、顔面紅潮などの閉経後症状として身体的に現れます。さらに、世界保健機関（WHO）が2022年に発表したデータによると、2022年には50歳以上の女性が全世界の女性と女児の26％を占めるとされています。世界中で50歳女性の負担が増加することで、最終的に更年期障害全体の負担が増加し、それによって、皮膚の紅潮、発汗、動悸などの更年期障害の管理に使用されるホルモン補充療法の需要が増加します。

当レポートでは、世界のホルモン補充療法市場について調査し、市場の概要とともに、治療法別、適応症別、投与経路別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 ホルモン補充療法市場レポートのイントロダクション

第2章 ホルモン補充療法市場のエグゼクティブサマリー

第3章 規制分析

第4章 ホルモン補充療法市場の主な要因分析

• ホルモン補充療法市場の促進要因
• ホルモン補充療法市場の抑制要因と課題
• ホルモン補充療法市場の機会

第5章 ホルモン補充療法市場におけるポーターのファイブフォース分析

第6章 ホルモン補充療法市場に対するCOVID-19の影響分析

第7章 ホルモン補充療法市場の概要

• 治療法別
• 適応症別
• 投与経路別
• 地域別

第8章 ホルモン補充療法市場の企業と製品プロファイル

• Abbott
• Novartis AG
• Pfizer Inc.
• Merck KGaA
• Bayer AG
• Halozyme Therapeutics, Inc.
• Eli Lilly and Company
• Viatris Inc.
• F.Hoffman-La Roche
• Novo Nordisk A/S
• Amgen Inc.
• Genentech, Inc.
• AbbVie Inc.
• Teva Pharmaceutical Industries Ltd.
• Dr. Reddy's Laboratories Ltd.
• Ascendis Pharma Endocrinology, Inc.
• Vista Pharma, Inc.
• Clarus Therapeutics, Inc.
• Gedeon Richter Plc
• Endo International plc

第9章 KOL の見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項とお問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: COVID-19 Impact Analysis on Hormone Replacement Therapy Market
• Table 3: Hormone Replacement Therapy Market Analysis in Global (2021-2030)
• Table 4: Hormone Replacement Therapy Market Analysis in Global by Therapy (2021-2030)
• Table 5: Hormone Replacement Therapy Market Analysis in Global by Indication (2021-2030)
• Table 6: Hormone Replacement Therapy Market Analysis in Global by Route of Administration (2021-2030)
• Table 7: Hormone Replacement Therapy Market Analysis in Global by Geography (2021-2030)
• Table 8: Hormone Replacement Therapy Market Analysis in North America (2021-2030)
• Table 9: Hormone Replacement Therapy Market Analysis in North America by Country (2021-2030)
• Table 10: Hormone Replacement Therapy Market Analysis in the US (2021-2030)
• Table 11: Hormone Replacement Therapy Market Analysis in Canada (2021-2030)
• Table 12: Hormone Replacement Therapy Market Analysis in Mexico (2021-2030)
• Table 13: Hormone Replacement Therapy Market Analysis in Europe (2021-2030)
• Table 14: Hormone Replacement Therapy Market Analysis in Europe by Country (2021-2030)
• Table 15: Hormone Replacement Therapy Market Analysis in France (2021-2030)
• Table 16: Hormone Replacement Therapy Market Analysis in Germany (2021-2030)
• Table 17: Hormone Replacement Therapy Market Analysis in the UK (2021-2030)
• Table 18: Hormone Replacement Therapy Market Analysis in Italy (2021-2030)
• Table 19: Hormone Replacement Therapy Market Analysis in Spain (2021-2030)
• Table 20: Hormone Replacement Therapy Market Analysis in the Rest of Europe (2021-2030)
• Table 21: Hormone Replacement Therapy Market Analysis in Asia-Pacific (2021-2030)
• Table 22: Hormone Replacement Therapy Market Analysis in Asia-Pacific by Country (2021-2030)
• Table 23: Hormone Replacement Therapy Market Analysis in China (2021-2030)
• Table 24: Hormone Replacement Therapy Market Analysis in Japan (2021-2030)
• Table 25: Hormone Replacement Therapy Market Analysis in India (2021-2030)
• Table 26: Hormone Replacement Therapy Market Analysis in Australia (2021-2030)
• Table 27: Hormone Replacement Therapy Market Analysis in South Korea (2021-2030)
• Table 28: Hormone Replacement Therapy Market Analysis in the Rest of Asia-Pacific (2021-2030)
• Table 29: Hormone Replacement Therapy Market Analysis in the Rest of the World (2021-2030)
• Table 30: Hormone Replacement Therapy Market Analysis in the Rest of the World by Region (2021-2030)
• Table 31: Hormone Replacement Therapy Market Analysis in the Middle East (2021-2030)
• Table 32: Hormone Replacement Therapy Market Analysis in Africa (2021-2030)
• Table 33: Hormone Replacement Therapy Market Analysis in South America (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: COVID-19 Impact Analysis on Hormone Replacement Therapy Market
• Figure 3: Hormone Replacement Therapy Market Analysis in Global (2021-2030)
• Figure 4: Hormone Replacement Therapy Market Analysis in Global by Therapy (2021-2030)
• Figure 5: Hormone Replacement Therapy Market Analysis in Global by Indication (2021-2030)
• Figure 6: Hormone Replacement Therapy Market Analysis in Global by Route of Administration (2021-2030)
• Figure 7: Hormone Replacement Therapy Market Analysis in Global by Geography (2021-2030)
• Figure 8: Hormone Replacement Therapy Market Analysis in North America (2021-2030)
• Figure 9: Hormone Replacement Therapy Market Analysis in North America by Country (2021-2030)
• Figure 10: Hormone Replacement Therapy Market Analysis in the US (2021-2030)
• Figure 11: Hormone Replacement Therapy Market Analysis in Canada (2021-2030)
• Figure 12: Hormone Replacement Therapy Market Analysis in Mexico (2021-2030)
• Figure 13: Hormone Replacement Therapy Market Analysis in Europe (2021-2030)
• Figure 14: Hormone Replacement Therapy Market Analysis in Europe by Country (2021-2030)
• Figure 15: Hormone Replacement Therapy Market Analysis in France (2021-2030)
• Figure 16: Hormone Replacement Therapy Market Analysis in Germany (2021-2030)
• Figure 17: Hormone Replacement Therapy Market Analysis in the UK (2021-2030)
• Figure 18: Hormone Replacement Therapy Market Analysis in Italy (2021-2030)
• Figure 19: Hormone Replacement Therapy Market Analysis in Spain (2021-2030)
• Figure 20: Hormone Replacement Therapy Market Analysis in the Rest of Europe (2021-2030)
• Figure 21: Hormone Replacement Therapy Market Analysis in Asia-Pacific (2021-2030)
• Figure 22: Hormone Replacement Therapy Market Analysis in Asia-Pacific by Country (2021-2030)
• Figure 23: Hormone Replacement Therapy Market Analysis in China (2021-2030)
• Figure 24: Hormone Replacement Therapy Market Analysis in Japan (2021-2030)
• Figure 25: Hormone Replacement Therapy Market Analysis in India (2021-2030)
• Figure 26: Hormone Replacement Therapy Market Analysis in Australia (2021-2030)
• Figure 27: Hormone Replacement Therapy Market Analysis in South Korea (2021-2030)
• Figure 28: Hormone Replacement Therapy Market Analysis in the Rest of Asia-Pacific (2021-2030)
• Figure 29: Hormone Replacement Therapy Market Analysis in the Rest of the World (2021-2030)
• Figure 30: Hormone Replacement Therapy Market Analysis in the Rest of the World by Region (2021-2030)
• Figure 31: Hormone Replacement Therapy Market Analysis in the Middle East (2021-2030)
• Figure 32: Hormone Replacement Therapy Market Analysis in Africa (2021-2030)
• Figure 33: Hormone Replacement Therapy Market Analysis in South America (2021-2030)
• Figure 34: Market Drivers
• Figure 35: Market Barriers
• Figure 36: Market Opportunities
• Figure 37: PORTER's Five Force Analysis

Hormone Replacement Therapy Market By Therapy (Estrogen Hormone Replacement, Growth Hormone Replacement, Thyroid Hormone Replacement, Testosterone Hormone Replacement, And Others), By Indication (Menopause, Hypothyroidism, Male Hypogonadism, Growth Hormone Deficiency, And Others), By Route Of Administration (Oral, Parenteral, And Transdermal), and by geography is expected to advance at a substantial CAGR forecast till 2030 owing to the increasing burden of menopause, thyroid disorder, osteoporosis, male hypogonadism, and others and the increasing research & developmental activities regarding the hormone replacement therapy across the globe

The global hormone replacement therapy is estimated to grow at a CAGR of 6.48% during the forecast period from 2024 to 2030. The hormone replacement therapy market is observing substantial market growth due to the growing burden of hormonal and targeted diseases such as menopause and osteoporosis, among others. Further, the increasing geriatric population base prone to low hormonal-related diseases, the rising awareness about menopause issues management among women, and the increasing demand for regenerative medicines such as anti-aging and reproductive-cycle boosting therapy will aid in surging the demand for hormonal replacement therapy. Additionally, the increasing research & developmental activities on hormonal replacement therapy, for instance, research on transdermal patches to improve the efficacy and other such research will increase the demand for hormonal replacement therapy in the market. Likewise, the increasing research & developmental activities along with the surging drug approvals and launches, the presence of key players in the market, and other factors will create a requisite for hormone replacement therapy in the market. Therefore, the market for hormone replacement therapy is estimated to grow at a substantial CAGR during the forecast period from 2024 to 2030.

Hormone Replacement Therapy Market Dynamics:

ONE OF THE KEY ASPECTS DRIVING THE HORMONE REPLACEMENT therapy market is the rising awareness among women about the management of menopausal issues, across the globe.

The global average age for menopause onset in women is around 50 years. Women's estrogen and progesterone production levels decrease significantly after the age of 50. The pituitary gland compensates for the decrease in estrogen and progesterone production by increasing the production of follicle-stimulating hormone (FSH). This manifests physically in women as post-menopausal symptoms such as flushing and others. Further, according to the data published in 2022 by the World Health Organization (WHO), it was stated that, in 2022, women aged 50 and over accounted for 26% of all women and girls globally. The increasing burden of women aged 50 across the globe will ultimately increase the overall menopausal load, thereby increasing the demand for hormonal replacement therapy used in the management of menopausal issues such as flushing of the skin, perspiration, and palpitations, among others.

Additionally, the growing R&D activities by the key players for the discovery of novel therapeutics to treat hormonal imbalances and rising product approvals are expected to aid in the growth of the studied market over the forecast period. Also, the increasing contribution of key players in the expansion of novel therapies is ultimately bringing about the introduction of new products in the market. For instance, in January 2022, Ascendis Pharma A/S received European Commission's market authorization for its drug SKYTROFA for the treatment of children and adolescents suffering from growth hormone disorders. This product is the first once-weekly treatment for growth hormone deficiency in the pediatric population.

Also, in June 2022, Halozyme Therapeutics, Inc. announced the commercial launch of TLANDO (testosterone undecanoate), an oral treatment indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. Thus, the rising number of approvals and launches will in turn upsurge the market of hormone replacement therapy during the forecast period.

Therefore, the factors stated above collectively will drive the overall hormone replacement therapy market throughout the forecast period from 2024-2030.

However, the high cost of drug development and launches, side effects associated with hormone replacement therapy, and the stringent regulatory approval process may prove to be challenging factors for the hormone replacement therapy market growth.

The hormone replacement therapy market was moderately impacted during the period of COVID- 19 pandemic. During the initial stage of the pandemic, the sale of the HRT suffered a downfall owing to the imposition of strict lockdown rules, and disruption in manufacturing, and supply. However, the government classified medicines and drugs under emergency products during the pandemic, thereby leading to an increase in their demand or sales. Moreover, with the involvement of online pharmacies, the sale of many over-the-counter medicines increased, impacting the market of hormone replacement drugs. Additionally, with the ease of lockdown restrictions, the upturn of resources and supply chain, the administration of the vaccine to the public, and the rising diagnosis of hormonal imbalance-related diseases, the demand for hormone replacement therapy increases and is anticipated to do the same during the forecast period from 2022 - 2028.

Hormone Replacement Therapy Market Segment Analysis:

Hormone Replacement Therapy Market by Therapy (Estrogen Hormone Replacement, Growth Hormone Replacement, Thyroid Hormone Replacement, Testosterone Hormone Replacement, and Others), Indication (Menopause, Hypothyroidism, Male Hypogonadism, Growth Hormone Deficiency, and Others), Route of Administration (Oral, Parenteral, and Transdermal), , and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the indication segment of the hormone replacement therapy market, the menopause segment is expected to have a significant revenue share in the year 2023. This was primarily owing to the increasing prevalence of menopause in women across the globe. Also, the intensifying launches and strategic investments, and other activities by the key players related to the segment will aid in driving its market during the forecast period.

As per the latest study conducted by the Meno Martha, International Menopause Directory, it was stated that worldwide, nearly 985 million women in 2020 were aged 50 and over, and this figure is expected to rise to 1.65 billion by 2050. The rising number of women aged 50 and above will increase the overall burden of menopausal-related issues thereby increasing the demand for various HRT. For instance, a combination therapy of levonorgestrel releasing-intrauterine system (LNG-IUS) with oral or percutaneous estrogen, low-dose combined oral contraceptives (COCs), and estrogen-progestogen therapy (EPT) is usually suggested for treating the symptoms of menopause during the menopausal transition. Thus, the increasing burden of women aged 50 and above will lead to an increase in the number of menopausal issues across the globe, ultimately leading to the increased demand for menopausal treating hormone replacement therapy.

Moreover, the presence of a robust number of menopausal issues treating hormonal replacement therapy in the pipeline will also drive market growth. For instance, nearly 20 drugs are currently under clinical trial, which may create a profitable opportunity for the key players in the upcoming years.

Further, various other strategic steps by the key players in the market will help in increasing the demand for hormone replacement therapy. For instance, in June 2022, Astellas Pharma Inc. announced that a New Drug Application (NDA) for fezolinetant has been submitted to the U.S. Food and Drug Administration (FDA). Fezolinetant is an investigational oral, non-hormonal compound seeking approval for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. VMS, characterized by hot flashes and/or night sweats, are common symptoms of menopause.

Also, in September 2022, Theramex announced the approval of Bijuva / Bijuve across Europe and the UK. Bijuva, body-identical hormone therapy treatment (HRT) for estrogen deficiency symptoms in postmenopausal women with an intact uterus and at least 12 months since last menses, which combines estradiol and progesterone in a single daily oral capsule.

Therefore, owing to the above-mentioned factors, the demand for menopausal treating hormone replacement drugs upsurges, thereby the category is expected to witness considerable growth eventually contributing to the overall growth of the global hormone replacement therapy market during the forecast period.

North America is expected to dominate the overall Hormone Replacement Therapy Market:

Among all the regions, North America is expected to dominate the global hormone replacement therapy market in the year 2023 and is expected to do the same during the forecast period from 2024-2030.

This can be ascribed to the increasing demand for hormone replacement drugs among women in the region owing to the increasing prevalence of menopausal-related issues. Further, the rising prevalence of growth deficiency disease, thyroid disorder, osteoporosis, hypogonadism, surging research and developmental activities in the region, presence of key domicile players in the region, and others are among the key factors that contribute to the growth of the hormone replacement therapy market in North America region during the forecast period from 2022 - 2028.

For instance, as per the latest study conducted by the American Thyroid Association, more than 12% of the United States population will develop a thyroid condition during their lifetime and around 20 million Americans have some form of thyroid disease. Also, as per the U.S. Department of Health and Human Services, it was estimated that in 2022 nearly 43,800 new cases of thyroid cancer will be diagnosed in the United States. During thyroid cancer, physicians may prescribe thyroid hormone therapy to prevent the cancer cells from growing. Thus, the increasing prevalence of thyroid-related issues in the United States will ultimately upsurge the demand for hormone replacement therapy in the region.

Further, major product launches, collaborative agreements between manufacturers, favorable reimbursement policies in the region, and others are among the factors responsible for the market growth in the region. For instance, in December 2020, the US FDA approved Thyquidity (levothyroxine) oral solution, of VistaPharm, for replacement therapy of primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism, along with an additional approval as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.

Also, in December 2020, the US FDA approved the Myovant Sciences' Orgovyx (relugolix), which is an orally administered treatment that works by blocking the pituitary gland from making hormones called luteinizing hormone and follicle-stimulating hormone, thus leading to the reduction in the amount of testosterone produced by the testicles. This aids in the treatment of adult patients with advanced prostate cancer.

Therefore, the interplay of the aforementioned factors above would provide a conducive growth environment for the North American region in the hormone replacement therapy market.

Hormone Replacement Therapy Market Key Players:

Some of the key market players operating in the hormone replacement therapy market include Abbott., Novartis AG, Pfizer Inc., Merck KGaA, Bayer AG, Halozyme Therapeutics, Inc., Eli Lilly and Company, Viatris Inc., F.Hoffman-La Roche, Novo Nordisk A/S, Amgen Inc., Genentech, Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Ascendis Pharma Endocrinology, Inc., Vista Pharma, Inc., Clarus Therapeutics, Inc., Gedeon Richter Plc, Endo International plc, and others.

Recent Developmental Activities in the Hormone Replacement Therapy Market:

In January 2022, Pfizer, Inc. and OPKO Health, Inc. received approval from the Ministry of Health, Labor and Welfare, Japan, for the commercialization of NGENLA to treat growth hormone disorders. This product is the next-generation long-acting growth hormone injection, with a treatment frequency of a once-a-week dosage.

In November 2022, I-MAB Biopharma Co., Ltd. entered into a collaboration with Jumpcan Pharmaceutical Group for the development & commercialization of eftansomatropin alfa (TJ101) in China. TJ101 is a long-acting recombinant human growth hormone, which is currently under phase 3 clinical trial for the treatment of pediatric growth hormone deficiency.

In August 2020, the U.S. FDA approved Sogroya (somapacitan-beco), an HGH replacement therapy product developed by Novo Nordisk A/S. This product is administered once a week through a subcutaneous route in adults diagnosed with growth hormone deficiency.

Key Takeaways from the Hormone Replacement Therapy Market Report Study

• Market size analysis for current hormone replacement therapy market size (2023), and market forecast for 5 years (2024-2030)
• The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the hormone replacement therapy market.
• Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the global hormone replacement therapy market.
• Various opportunities available for the other competitor in the hormone replacement therapy market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030.
• Which are the top-performing regions and countries in the current hormone replacement therapy market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for hormone replacement therapy market growth in the coming future?

Target Audience who can be benefited from this Hormone Replacement Therapy Market Report Study

• Hormone replacement therapy providers
• Research organizations and consulting companies
• Hormone replacement therapy-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in hormone replacement therapy
• Various end users who want to know more about the hormone replacement therapy market and the latest developments in the hormone replacement therapy market.

Frequently Asked Questions for the Hormone Replacement Therapy Market:

1. What is hormone replacement therapy?

Hormone replacement therapy (HRT) is a treatment technique for replacing and/or replenishing hormones in the human body, which are at inadequate levels than those required for the normal physiology of the human body.

2. What is the global market for hormone replacement therapy market?

The global hormone replacement therapy is estimated to grow at a CAGR of 6.48% during the forecast period from 2024 to 2030.

3. What are the drivers for the global hormone replacement therapy market?

The hormone replacement therapy market is witnessing positive market growth owing to the factors such as the growing burden of targeted and hormonal disorders, increasing awareness about post-menopausal issues among women and other hormone deficiency diseases, surging demand for advanced drug delivery systems such as transdermal drugs or gels with greater efficacy, increased demand of regenerative medicines such as anti-aging and reproductive-cycle boosting therapy, increasing new drug launches and approvals, presence of key players in the market, and others will create an exigency for the hormone replacement therapy market.

4. Who are the key players operating in the global hormone replacement therapy market?

Some of the key market players operating in the hormone replacement therapy market include Abbott., Novartis AG, Pfizer Inc., Merck KGaA, Bayer AG, Halozyme Therapeutics, Inc., Eli Lilly and Company, Viatris Inc., F.Hoffman-La Roche, Novo Nordisk A/S, Amgen Inc., Genentech, Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Ascendis Pharma Endocrinology, Inc., Vista Pharma, Inc., Clarus Therapeutics, Inc., Gedeon Richter Plc, Endo International plc, and others.

5. Which region has the highest share of the hormone replacement therapy market?

Among all the regions, North America is estimated to hold a significant revenue share in the global hormone replacement therapy market. This can be ascribed to the increasing demand for hormone replacement drugs among women in the region owing to the increasing prevalence of menopausal-related issues. Further, the rising prevalence of growth deficiency disease, thyroid disorder, osteoporosis, hypogonadism, surging research and developmental activities in the region, and the presence of key domicile players in the region are the reasons which act as a supportive factor for the North America hormone replacement therapy market growth.

Table of Contents

1.Hormone Replacement Therapy Market Report Introduction

2. Hormone Replacement Therapy Market Executive Summary

• 2.1. Scope of the Study
• 2.2. Market at Glance
• 2.3. Competitive Assessment

3. Regulatory Analysis

4. Hormone Replacement Therapy Market Key Factors Analysis

• 4.1. Hormone Replacement Therapy Market Drivers
  • 4.1.1. The growing burden of targeted and hormonal disorders
  • 4.1.2. Increasing awareness about post-menopausal issues among women and other hormone deficiency diseases
  • 4.1.3. Surging demand for advanced drug delivery systems such as transdermal drugs or gels with greater efficacy
  • 4.1.4. Increased demand for regenerative medicines such as anti-aging and reproductive-cycle boosting therapy
• 4.2. Hormone Replacement Therapy Market Restraints and Challenges
  • 4.2.1. High cost of drug development and launches
  • 4.2.2. Side effects associated with hormonal replacement therapy (HRT)
  • 4.2.3. A stringent regulatory approval process
• 4.3. Hormone Replacement Therapy Market Opportunities
  • 4.3.1. Availability of a robust drug in the pipeline
  • 4.3.2. Increasing government support for research and development activities for hormonal replacement therapy drugs

5. Hormone Replacement Therapy Market Porter's Five Forces Analysis

• 5.1. Bargaining Power of Suppliers
• 5.2. Bargaining Power of Consumers
• 5.3. Threat of New Entrants
• 5.4. Threat of Substitutes
• 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Hormone Replacement Therapy Market

7. Hormone Replacement Therapy Market Layout

• 7.1. By Therapy
  • 7.1.1. Estrogen Hormone Replacement
  • 7.1.2. Growth Hormone Replacement
  • 7.1.3. Thyroid Hormone Replacement
  • 7.1.4. Testosterone Hormone Replacement
  • 7.1.5. Others
• 7.2. By Indication
  • 7.2.1. Menopause
  • 7.2.2. Hypothyroidism
  • 7.2.3. Male Hypogonadism
  • 7.2.4. Growth Hormone Deficiency
  • 7.2.5. Others
• 7.3. By Route of Administration
  • 7.3.1. Oral
  • 7.3.2. Parenteral
  • 7.3.3. Transdermal
• 7.4. By Geography
  • 7.4.1. North America
    • 7.4.1.1. United States Hormone Replacement Therapy Market in USD million (2021-2030)
    • 7.4.1.2. Canada Hormone Replacement Therapy Market in USD million (2021-2030)
    • 7.4.1.3. Mexico Hormone Replacement Therapy Market in USD million (2021-2030)
  • 7.4.2. Europe
    • 7.4.2.1. France Hormone Replacement Therapy Market in USD million (2021-2030)
    • 7.4.2.2. Germany Hormone Replacement Therapy Market in USD million (2021-2030)
    • 7.4.2.3. United Kingdom Hormone Replacement Therapy Market in USD million (2021-2030)
    • 7.4.2.4. Italy Hormone Replacement Therapy Market in USD million (2021-2030)
    • 7.4.2.5. Spain Hormone Replacement Therapy Market in USD million (2021-2030)
    • 7.4.2.6. Rest of Europe Hormone Replacement Therapy Market in USD million (2021-2030)
  • 7.4.3. Asia-Pacific
    • 7.4.3.1. China Hormone Replacement Therapy Market in USD million (2021-2030)
    • 7.4.3.2. Japan Hormone Replacement Therapy Market in USD million (2021-2030)
    • 7.4.3.3. India Hormone Replacement Therapy Market in USD million (2021-2030)
    • 7.4.3.4. Australia Hormone Replacement Therapy Market in USD million (2021-2030)
    • 7.4.3.5. South Korea Hormone Replacement Therapy Market in USD million (2021-2030)
    • 7.4.3.6. Rest of Asia Pacific Hormone Replacement Therapy Market in USD million (2021-2030)
  • 7.4.4. Rest of the World (RoW)
    • 7.4.4.1. Middle East Hormone Replacement Therapy Market in USD million (2021-2030)
    • 7.4.4.2. Africa Hormone Replacement Therapy Market in USD million (2021-2030)
    • 7.4.4.3. South America Hormone Replacement Therapy Market in USD million (2021-2030)

8. Hormone Replacement Therapy Market Company and Product Profiles

• 8.1. Abbott.
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Novartis AG
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. Pfizer Inc.
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. Merck KGaA
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. Bayer AG
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Halozyme Therapeutics, Inc.
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. Eli Lilly and Company
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. Viatris Inc.
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. F.Hoffman-La Roche
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. Novo Nordisk A/S
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. Amgen Inc.
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. Genentech, Inc.
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. AbbVie Inc.
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. Teva Pharmaceutical Industries Ltd.
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy
• 8.15. Dr. Reddy's Laboratories Ltd.
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4. Product Listing
  • 8.15.5. Entropy
• 8.16. Ascendis Pharma Endocrinology, Inc.
  • 8.16.1. Company Overview
  • 8.16.2. Company Snapshot
  • 8.16.3. Financial Overview
  • 8.16.4. Product Listing
  • 8.16.5. Entropy
• 8.17. Vista Pharma, Inc.
  • 8.17.1. Company Overview
  • 8.17.2. Company Snapshot
  • 8.17.3. Financial Overview
  • 8.17.4. Product Listing
  • 8.17.5. Entropy
• 8.18. Clarus Therapeutics, Inc.
  • 8.18.1. Company Overview
  • 8.18.2. Company Snapshot
  • 8.18.3. Financial Overview
  • 8.18.4. Product Listing
  • 8.18.5. Entropy
• 8.19. Gedeon Richter Plc
  • 8.19.1. Company Overview
  • 8.19.2. Company Snapshot
  • 8.19.3. Financial Overview
  • 8.19.4. Product Listing
  • 8.19.5. Entropy
• 8.20. Endo International plc
  • 8.20.1. Company Overview
  • 8.20.2. Company Snapshot
  • 8.20.3. Financial Overview
  • 8.20.4. Product Listing
  • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us